ACR Appropriateness Criteria(R)-Anal Cancer Journal Article

Authors: Expert Panel on Radiation Oncology-Rectal/Anal Cancer; Hong, T. S.; Pretz, J. L.; Herman, J. M.; Abdel-Wahab, M; Azad, N; Blackstock, A. W.; Das, P; Goodman, K. A.; Jabbour, S. K.; Jones, W. E., 3rd; Konski, A. A.; Koong, A. C.; Rodriguez-Bigas, M; Small, W., Jr; Thomas, C. R., Jr; Zook, J.; Suh, W. W.
Article Title: ACR Appropriateness Criteria(R)-Anal Cancer
Abstract: The management of anal cancer is driven by randomized and nonrandomized clinical trials. However, trials may present conflicting conclusions. Furthermore, different clinical situations may not be addressed in certain trials because of eligibility inclusion criteria. Although prospective studies point to the use of definitive 5-fluorouracil and mitomycin C-based chemoradiation as a standard, some areas remain that are not well defined. In particular, management of very early stage disease, radiation dose, and the use of intensity-modulated radiation therapy remain unaddressed by phase III studies. The American College of Radiology (ACR) Appropriateness Criteria(R) are evidence-based guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.
Journal Title: Gastrointestinal cancer research : GCR
Volume: 7
Issue: 1
ISSN: 1934-7987; 1934-7820
Publisher: Unknown  
Journal Place: United States
Date Published: 2014
Start Page: 4
End Page: 14
Language: eng
Notes: LR: 20140224; JID: 101300691; OID: NLM: PMC3924766; OTO: NOTNLM; ppublish
LUC Authors
  1. Nasrin Azad
    13 Azad
  2. William Small
    155 Small